Science Now

‘Absolutely remarkable’: No one who got Moderna’s vaccine in trial developed severe COVID-19

Science’s COVID-19 reporting is supported by the Pulitzer Center and the Heising-Simons Foundation. Continuing the spate of stunning news about COVID-19 vaccines, the biotech company Moderna announced the final results of the 30,000-person efficacy trial for its candidate in a press release today: Only 11 people who received two doses of the vaccine developed COVID-19 symptoms after being infected with the pandemic coronavirus, versus 185 symptomatic cases in a placebo group. That is an efficacy of 94.1%, the company says, far above what many vaccine scientists were expecting just a few weeks ago.
Picture for ‘Absolutely remarkable’: No one who got Moderna’s vaccine in trial developed severe COVID-19

Moderna applies for FDA authorization for its Covid-19 vaccine

(CNN) — Pharmaceutical company Moderna applied on Monday to the US Food and Drug Administration for authorization of its Covid-19 vaccine. The company asked the FDA to review an expanded data set showing the vaccine is 94.1% effective at preventing Covid-19 and 100% effective at preventing severe cases of the disease.
Picture for Moderna applies for FDA authorization for its Covid-19 vaccine

More Good News For Moderna's COVID-19 Vaccine Candidate

The biotech company Moderna released new data Monday morning that strengthens the case for its COVID-19 vaccine. It concludes the vaccine is 94 percent effective – and strongly protects against serious illness. Based on these latest findings, the company plans to submit an application for emergency use authorization to the Food and Drug Administration today.

Moderna's COVID-19 Vaccine Shines In Clinical Trial

A second COVID-19 vaccine now also appears highly effective in preventing illness following exposure to the virus that causes the disease. The biotech company Moderna, Inc., said Monday that its experimental vaccine was 94.5% effective in preventing disease, according to an analysis of its clinical trial. The news comes a...
NIH Director's Blog

Promising Interim Results from Clinical Trial of NIH-Moderna COVID-19 Vaccine

An independent data and safety monitoring board (DSMB) overseeing the Phase 3 trial of the investigational COVID-19 vaccine known as mRNA-1273 reviewed trial data and shared its interim analysis with the trial oversight group on Nov. 15, 2020. This interim review of the data suggests that the vaccine is safe and effective at preventing symptomatic COVID-19 in adults. The interim analysis comprised 95 cases of symptomatic COVID-19 among volunteers. The DSMB reported that the candidate was safe and well-tolerated and noted a vaccine efficacy rate of 94.5%. The findings are statistically significant, meaning they are likely not due to chance. 90 of the cases occurred in the placebo group and 5 occurred in the vaccinated group. There were 11 cases of severe COVID-19 out of the 95 total, all of which occurred in the placebo group.

From Idea To Mass Production, Moderna's COVID Vaccine Will Come From Massachusetts

The COVID-19 vaccine that was dreamed up and developed by Massachusetts-based Moderna will also be manufactured in the state. "The vast majority of the U.S. production will be done in Massachusetts," Moderna co-founder Noubar Afeyan told GBH News. Afeyan is the founder and CEO of Flagship Pioneering, a biotech venture capital firm that founded Moderna and more than 50 other life science and technology startups.

Why Moderna Stock Surged Today

Shares of Moderna (NASDAQ:MRNA) soared on Monday after the biotech said an analysis of its phase 3 study confirmed its experimental COVID-19 vaccine to be highly effective at preventing the dangerous disease. As of 2 p.m. EST, Moderna's stock was up more than 16%. So what. A primary efficacy analysis...

Stocks making the biggest moves premarket: Moderna, IHS Markit, Slack & more

Check out the companies making headlines before the bell:. Moderna — Shares Moderna rose more than 11% in premarket trading after the drugmaker said new data confirms the vaccine is more than 94% effective in preventing Covid-19. Moderna plans to request emergency clearance from the Food and Drug Administration on Monday.